Myelodysplastic Syndromes

Phuong L Nguyen, Robert Paul Hasserjian

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Clinically, patients present with cytopenia(s) and a variable probability of progression to acute myeloid leukemia (AML). Pathologically, there are usually dysplastic morphologic features in one or more of the three hematopoietic lineages, with or without an accompanying increase in myeloblasts in the peripheral blood and/or bone marrow, but at a blast percentage lower than the 20% threshold defining AML. MDS can arise de novo or can be therapy related. Accurate diagnosis and classification of MDS require integration of the microscopic examination of well-prepared and well-stained peripheral blood, bone marrow aspirate, and biopsy slides with the clinical history, including medical and family history, and laboratory and cytogenetic results; flow cytometry immunophenotyping and molecular genetic analyses can provide valuable supportive diagnostic data. Multiple prognostic scoring systems have been devised to help in the management of patients with MDS, with additional contribution likely forthcoming from accumulating data on molecular genetic analyses.

Original languageEnglish (US)
Title of host publicationHematopathology
Subtitle of host publicationA Volume in the Series: Foundations in Diagnostic Pathology
PublisherElsevier Inc.
Pages539-563.e2
ISBN (Electronic)9780323512312
ISBN (Print)9780323479134
DOIs
StatePublished - Dec 1 2017

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Molecular Biology
Medical History Taking
Bone Marrow
Granulocyte Precursor Cells
Immunophenotyping
Hematopoiesis
Hematopoietic Stem Cells
Cytogenetics
Flow Cytometry
Biopsy
Therapeutics

Keywords

  • Del(5q)
  • Excess blasts
  • Myelodysplasia
  • Myelodysplastic syndrome
  • Pre-leukemia
  • Refractory anemia
  • Refractory cytopenia
  • Ring sideroblasts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nguyen, P. L., & Hasserjian, R. P. (2017). Myelodysplastic Syndromes. In Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology (pp. 539-563.e2). Elsevier Inc.. https://doi.org/10.1016/B978-0-323-47913-4.00018-5

Myelodysplastic Syndromes. / Nguyen, Phuong L; Hasserjian, Robert Paul.

Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Inc., 2017. p. 539-563.e2.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nguyen, PL & Hasserjian, RP 2017, Myelodysplastic Syndromes. in Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Inc., pp. 539-563.e2. https://doi.org/10.1016/B978-0-323-47913-4.00018-5
Nguyen PL, Hasserjian RP. Myelodysplastic Syndromes. In Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Inc. 2017. p. 539-563.e2 https://doi.org/10.1016/B978-0-323-47913-4.00018-5
Nguyen, Phuong L ; Hasserjian, Robert Paul. / Myelodysplastic Syndromes. Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Inc., 2017. pp. 539-563.e2
@inbook{305c1491e6ff4c31af56a884bd4cf974,
title = "Myelodysplastic Syndromes",
abstract = "The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Clinically, patients present with cytopenia(s) and a variable probability of progression to acute myeloid leukemia (AML). Pathologically, there are usually dysplastic morphologic features in one or more of the three hematopoietic lineages, with or without an accompanying increase in myeloblasts in the peripheral blood and/or bone marrow, but at a blast percentage lower than the 20{\%} threshold defining AML. MDS can arise de novo or can be therapy related. Accurate diagnosis and classification of MDS require integration of the microscopic examination of well-prepared and well-stained peripheral blood, bone marrow aspirate, and biopsy slides with the clinical history, including medical and family history, and laboratory and cytogenetic results; flow cytometry immunophenotyping and molecular genetic analyses can provide valuable supportive diagnostic data. Multiple prognostic scoring systems have been devised to help in the management of patients with MDS, with additional contribution likely forthcoming from accumulating data on molecular genetic analyses.",
keywords = "Del(5q), Excess blasts, Myelodysplasia, Myelodysplastic syndrome, Pre-leukemia, Refractory anemia, Refractory cytopenia, Ring sideroblasts",
author = "Nguyen, {Phuong L} and Hasserjian, {Robert Paul}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/B978-0-323-47913-4.00018-5",
language = "English (US)",
isbn = "9780323479134",
pages = "539--563.e2",
booktitle = "Hematopathology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Myelodysplastic Syndromes

AU - Nguyen, Phuong L

AU - Hasserjian, Robert Paul

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Clinically, patients present with cytopenia(s) and a variable probability of progression to acute myeloid leukemia (AML). Pathologically, there are usually dysplastic morphologic features in one or more of the three hematopoietic lineages, with or without an accompanying increase in myeloblasts in the peripheral blood and/or bone marrow, but at a blast percentage lower than the 20% threshold defining AML. MDS can arise de novo or can be therapy related. Accurate diagnosis and classification of MDS require integration of the microscopic examination of well-prepared and well-stained peripheral blood, bone marrow aspirate, and biopsy slides with the clinical history, including medical and family history, and laboratory and cytogenetic results; flow cytometry immunophenotyping and molecular genetic analyses can provide valuable supportive diagnostic data. Multiple prognostic scoring systems have been devised to help in the management of patients with MDS, with additional contribution likely forthcoming from accumulating data on molecular genetic analyses.

AB - The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Clinically, patients present with cytopenia(s) and a variable probability of progression to acute myeloid leukemia (AML). Pathologically, there are usually dysplastic morphologic features in one or more of the three hematopoietic lineages, with or without an accompanying increase in myeloblasts in the peripheral blood and/or bone marrow, but at a blast percentage lower than the 20% threshold defining AML. MDS can arise de novo or can be therapy related. Accurate diagnosis and classification of MDS require integration of the microscopic examination of well-prepared and well-stained peripheral blood, bone marrow aspirate, and biopsy slides with the clinical history, including medical and family history, and laboratory and cytogenetic results; flow cytometry immunophenotyping and molecular genetic analyses can provide valuable supportive diagnostic data. Multiple prognostic scoring systems have been devised to help in the management of patients with MDS, with additional contribution likely forthcoming from accumulating data on molecular genetic analyses.

KW - Del(5q)

KW - Excess blasts

KW - Myelodysplasia

KW - Myelodysplastic syndrome

KW - Pre-leukemia

KW - Refractory anemia

KW - Refractory cytopenia

KW - Ring sideroblasts

UR - http://www.scopus.com/inward/record.url?scp=85054449756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054449756&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-47913-4.00018-5

DO - 10.1016/B978-0-323-47913-4.00018-5

M3 - Chapter

SN - 9780323479134

SP - 539-563.e2

BT - Hematopathology

PB - Elsevier Inc.

ER -